: Neuromuscular diseases are severe disorders affecting the peripheral nervous system, usually driving to death in a limited time. Many new drugs, through RNA-interference technology, are revolutionizing the prognosis and quality of life for these patients. Nevertheless, given the increased life expectancy, some new issues and phenotypes are expected to be revealed. In the transthyretin-mediated hereditary amyloidosis (ATTR-v, "v" for "variant"), the RNA interference was demonstrated to effectively reduce the hepatic synthesis of transthyretin, with a significant increase in disease progression in terms of polyneuropathy and cardiomyopathy. The increased life expectancy could promote the involvement of organs where the extra-hepatic transthyretin is deposited, such as the brain and eye, which are probably not targeted by the available treatments. All these issues are discussed in this editorial.
RNA Interference and Neuromuscular Diseases: A Focus on Hereditary Transthyretin Amyloidosis / Ceccanti, Marco; Inghilleri, Maurizio. - In: CURRENT GENE THERAPY. - ISSN 1566-5232. - 23:(2023). [10.2174/1566523223666230913110011]
RNA Interference and Neuromuscular Diseases: A Focus on Hereditary Transthyretin Amyloidosis
Marco Ceccanti
Primo
Writing – Original Draft Preparation
;Maurizio InghilleriUltimo
Writing – Review & Editing
2023
Abstract
: Neuromuscular diseases are severe disorders affecting the peripheral nervous system, usually driving to death in a limited time. Many new drugs, through RNA-interference technology, are revolutionizing the prognosis and quality of life for these patients. Nevertheless, given the increased life expectancy, some new issues and phenotypes are expected to be revealed. In the transthyretin-mediated hereditary amyloidosis (ATTR-v, "v" for "variant"), the RNA interference was demonstrated to effectively reduce the hepatic synthesis of transthyretin, with a significant increase in disease progression in terms of polyneuropathy and cardiomyopathy. The increased life expectancy could promote the involvement of organs where the extra-hepatic transthyretin is deposited, such as the brain and eye, which are probably not targeted by the available treatments. All these issues are discussed in this editorial.File | Dimensione | Formato | |
---|---|---|---|
BMS-CGT-2023-69-MS (2).pdf
accesso aperto
Note: Ceccanti_RNA Interference_2023
Tipologia:
Documento in Post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
607.82 kB
Formato
Adobe PDF
|
607.82 kB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.